BTA test in the diagnosis and follow-up of patients with bladder cancer

There are several diagnostic procedures that can identify patients with recurrent or primary transitional cell carcinoma (TCC) of the bladder. Cystoscopy is the best tool and the golden standard against which the other tools have to be compared. In our experience the BTA test has proved more accurate than urinary cytology, above all in diagnosing low-grade, low-stage TCC of the bladder.

Download Full-text

Does Urine Cytology Still have a Role?

Urologia Journal ◽

10.1177/039156030507200301 ◽

2005 ◽

Vol 72 (3) ◽

pp. 301-306

Author(s):

M. Ciaccia ◽

R. Bertoloni ◽

F. Pinto ◽

A. Calpista ◽

P.F. Bassi

Keyword(s):

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Carcinoma In Situ ◽

Transitional Cell ◽

High Sensitivity ◽

Urine Cytology ◽

Low Grade ◽

New Methods

Urine cytology is a reliable and well known tool in the diagnosis and follow-up of patients with transitional cell carcinoma even if it has high sensitivity only in high grade tumors and carcinoma in situ. In order to improve sensitivity of this test in patients with low grade tumors, new methods such as cytometry, microsatellite assays, Immunocyt®, fuorescence in-situ hybridization and Thin-Prep monolayer have been developed. These new assays will be able to increase the cytology detection rate and to predict the outcome of transitional cell carcinoma.

Download Full-text

Clinical evaluation of nuclear matrix protein 22 as urinary marker of transitional cell carcinoma of bladder

Urologia Journal ◽

10.1177/039156030807500104 ◽

2008 ◽

Vol 75 (1) ◽

pp. 20-23

Author(s):

R.F. Liotta ◽

F. Mangiapia ◽

M.L. Tarantino ◽

S. Di Meo ◽

V. Mirone ◽

...

Keyword(s):

Transitional Cell Carcinoma ◽

Tumor Marker ◽

Cell Carcinoma ◽

Nuclear Matrix ◽

Matrix Protein ◽

Transitional Cell ◽

Cancer Surveillance ◽

Urinary Cytology ◽

Nuclear Matrix Protein

Objectives. Biomarkers (BTA, NMP22, FDP etc.) have been and continue to be evaluated as adjuncts or substitutes for cystoscopy, which is invasive and uncomfortable for some patients. Nuclear matrix protein-22 (NMP22) is involved in the regulation of nuclear processes. The main objective of the present study is to evaluate the clinical utility of urinary NMP22 as a tumor marker in the follow-up of transitional cell carcinoma (TCC) of the bladder. Materials and Methods. The study included 62 patients undergoing follow-up, who had had TCC of bladder but who were disease-free at the beginning of the study, as confirmed by cystoscopy. Urine samples were collected for urinary cytology and NMP22 test before the cystoscopy. All samples were processed according to the instructions provided with the manufacturer's kit instructions. Results. 12 cases of TCC recurrences were detected with biopsy. Cystoscopy was positive in 8 cases, NMP22 test was positive in 11 cases, and in only one case the cytopathology yielded positive results. In 14 cases NMP22 resulted as false positive. Conclusions. Urinary NMP22 appeared to be a potential tumor marker for detecting TCC of the bladder, which might rise the sensitivity of cystoscopy especially in high-grade cancer surveillance more than cytology might do.

Download Full-text

Usefulness of the UBCTM (urinary bladder cancer) test compared to urinary cytology for transitional cell carcinoma of the bladder in patients with hematuria

European Urology Supplements ◽

10.1016/s1569-9056(02)80304-9 ◽

2002 ◽

Vol 1 (1) ◽

pp. 79 ◽

Cited By ~ 1

Author(s):

Se-il Jung ◽

Gil Myung Cheol ◽

Kang Do Young ◽

Rha Seo Hee ◽

Seong Youl Koon ◽

...

Keyword(s):

Bladder Cancer ◽

Urinary Bladder ◽

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Transitional Cell ◽

Urinary Bladder Cancer ◽

Urinary Cytology ◽

Carcinoma Of The Bladder

Download Full-text

Preliminary comparative considerations about urinary cytology and the Bard BTA test in the diagnosis and follow-up of superficial bladder cancer

Urologia Journal ◽

10.1177/039156039506201s23 ◽

1995 ◽

Vol 62 (1_suppl) ◽

pp. 88-90

Author(s):

C. Boccafoschi ◽

F. Montefiore ◽

S. Treffiletti ◽

D. Signorello ◽

A. Langé

Keyword(s):

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Bladder Tumour ◽

Transitional Cell ◽

Latex Agglutination ◽

Urinary Cytology ◽

In Vitro Test ◽

Carcinoma Of The Bladder

— The value of urinary cytology in the diagnosis and follow-up of superficial transitional cell carcinoma of the bladder is well known. Results of traditional cytologic examinations may be affected by the different methods of urine collection, preservation, manipulation and observation of the samples so that more objective tools are desirable. The aim of this study in to compare the traditional cytologic examinations with a new diagnostic in-vitro test (Bard BTA test), which can detect antigen complexes in the urine due to the contact of the tumour cells with the basement membrane. The Bard BTA test is a latex agglutination assay which identifies the bladder tumour antigens in the urine. The result of the agglutination reaction (positive or negative) may be visually distinguished by the variation in colour of special strips of testing paper. The Authors report on a preliminary experience in the follow-up of patients with previous superficial transitional cell carcinoma of the bladder: they compare the results of traditional cytology, the Bard BTA test and cystoscopy and have found agreement in 70% of the cases.

Download Full-text

NBI-assisted cystoscopy to improve follow-up of patients with transitional cell carcinoma of the bladder.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.2_suppl.400 ◽

2016 ◽

Vol 34 (2_suppl) ◽

pp. 400-400

Author(s):

Andreas Eisenhardt ◽

Lucas Hirner ◽

Herbert Ruebben

Keyword(s):

Bladder Cancer ◽

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Narrow Band Imaging ◽

Transitional Cell ◽

White Light Endoscopy ◽

Second Look ◽

Number Of Patients ◽

Carcinoma Of The Bladder

400 Background: Narrow Band Imaging (NBI) is a new technique of urethrocystoscopy, in which only a certain bandwidths of illumination (415 (blue) and 540nm (green)) of the spectrum is used to detect urothelial carcinoma. The aim of the investigation was to analyse the potential benefit of NBI in the follow up of patients with transitional cell carcinoma of the bladder. Methods: In the time between August 2013 until August 2014, patients with history of transitional cell carcinoma of the bladder, who presented for follow-up cystoscopy , were either examined via flexible white light endoscopy [WLE] plus second look WLE (n = 317, controls) or second look NBI-cystoscopy alone (n = 308) in the same session. Results: Rates of recurrences were similiar in both groups (NBI 95 (25%); WLE 85 (26.8%)). NBI after WLE identified more tumours in 21 patients (6.1 vs. 3.81). In 9 patients NBI showed no vascularization in suspicious areas. In the control arm, in 9 cases more tumours (4,67 vs. 3.33) were identified in the second WLE. After macroscopical identification of a recurrence, the time since the last resection was measured (WLE 10,67 months, NBI 16,85 months). Conclusions: While the number of patients with recurrent bladder cancer is not influenced by the use of NBI, the additional use of NBI in the follow-up cystoscopy of patients after transurethral resection of superficial bladder cancer (TUR) leads to an increased number of detected tumors. A part of the additionally detected tumors can be explained by the double examination. In addition NBI appears to provide a hint in individual cases whether a TUR is necessary at all.

Download Full-text

Upper tract transitional cell carcinoma following or related to bladder cancer: Controversies

Urologia Journal ◽

10.1177/039156039606300103 ◽

1996 ◽

Vol 63 (1) ◽

pp. 25-28

Author(s):

S. Cosciani Cunico ◽

E. Frego ◽

M. Scanzi ◽

T. Zanotelli ◽

E. Panizza ◽

...

Keyword(s):

Bladder Cancer ◽

Urinary Tract ◽

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Vesicoureteral Reflux ◽

Transitional Cell ◽

Latency Period ◽

Upper Urinary Tract

— The incidence of upper urinary tract transitional cell carcinoma (UTTCC) following a bladder cancer has been studied in 1731 urothelial tumours from 1984 to 1995. The UTTCC were 88: 59 primitive, 6 synchronous and 23 metachronous after a bladder cancer (1672). Of the 23 metachronous UTTCC, 17 followed TURBT (17/1310 = 1.3%): the latency period was very long (64.8 months); grading and staging were mostly similar to the foregoing bladder tumours. A vesicoureteral reflux raised the metachronous UTTCC rate to 17.6%. A neoplastic distal ureter was found during radical cystectomy in 2.24%. During the follow-up of 362 radical cystectomies 6 (1.65%) metachronous UTTCC were recorded. A metachronous UTTCC is always a poor prognostic sign. There are some controversies concerning this topic such as: the role of IVP and urine cytology in the follow-up of bladder cancer, the management of a vesicoureteral reflux in bladder cancer and the choice of a urinary diversion in the event of an upper urinary tract at high risk for UTTCC.

Download Full-text

Metastatic bladder neoplasms treated with stereotactic body radiosurgery.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.2_suppl.397 ◽

2016 ◽

Vol 34 (2_suppl) ◽

pp. 397-397 ◽

Cited By ~ 1

Author(s):

Ariel Joseph Lederman ◽

Mordecha Loksen ◽

Thomas Lowinger ◽

Daniel Izon ◽

Gilbert S. Lederman

Keyword(s):

Bladder Cancer ◽

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Transitional Cell ◽

Bladder Neoplasms ◽

Invasive Technique ◽

Metastatic Bladder Cancer ◽

Body Radiosurgery ◽

Significant Difference

397 Background: Stereotactic Body Radiosurgery (SBR) as treatment for metastatic bladder cancer delivers high dose radiation precisely to the site of cancer. In our prospective data analysis, 20 sites of extravesical bladder cancer treated with SBR were analyzed. Methods: Twenty metastatic bladder neoplasms were treated in 15 patients. Sixteen were transitional cell carcinoma, 2 adenocarcinoma, 1 squamous cell carcinoma, and 1 rhabdomyosarcoma. Ages ranged from 39 to 82 years (mean 64) with 4 females and 11 males. Tumor volumes ranged from 10.2 to 563 cc (mean 129.8 cc). Patients were treated with 500-900 cGy (median 800) in 5-8 fractions (median 5) for a total dose of 3000-4500 cGy (median 4000). Cancers were radiographically evaluated with contrast CT and/or MRI studies and reviewed independently by radiologists. Disease control is defined as cessation of growth, shrinkage or disappearance of the tumor after treatment. Results: Follow-up ranged from 1 to 20 months (mean 8 months). The overall control rate was 90%. Both patients who did not respond to treatment were males with transitional cell carcinoma. By dose, volume, age, sex and prior treatment, there was no statistically significant difference in outcome among the 20 patients treated. Conclusions: SBR for metastatic bladder cancer offers a well-tolerated, non-invasive technique with a high rate of tumor control. Patients continue to be evaluated for longer follow up, possible benefits of local control and potential survival advantage. SBR remains an option for those whom standard approaches have not produced desired results or in patients seeking an alternative to surgical or chemotherapeutic treatment.

Download Full-text